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The molecular architecture of amyloids formed in vivo can be
interrogated using luminescent conjugated oligothiophenes (LCOs),
a unique class of amyloid dyes. When bound to amyloid, LCOs yield
fluorescence emission spectra that reflect the 3D structure of the
protein aggregates. Given that synthetic amyloid-β peptide (Aβ) has
been shown to adopt distinct structural conformations with different
biological activities, we asked whether Aβ can assume structurally
and functionally distinct conformations within the brain. To this
end, we analyzed the LCO-stained cores of β-amyloid plaques in post-
mortem tissue sections from frontal, temporal, and occipital neocor-
tices in 40 cases of familial Alzheimer’s disease (AD) or sporadic
(idiopathic) AD (sAD). The spectral attributes of LCO-bound plaques
varied markedly in the brain, but the mean spectral properties of the
amyloid cores were generally similar in all three cortical regions of
individual patients. Remarkably, the LCO amyloid spectra differed
significantly among some of the familial and sAD subtypes, and be-
tween typical patients with sAD and those with posterior cortical
atrophy AD. Neither the amount of Aβ nor its protease resistance
correlated with LCO spectral properties. LCO spectral amyloid pheno-
types could be partially conveyed to Aβ plaques induced by experi-
mental transmission in a mouse model. These findings indicate that
polymorphic Aβ-amyloid deposits within the brain cluster as clouds of
conformational variants in different AD cases. Heterogeneity in the
molecular architecture of pathogenic Aβ among individuals and in
etiologically distinct subtypes of AD justifies further studies to assess
putative links between Aβ conformation and clinical phenotype.
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Despite a common origin in the structural corruption and ac-cumulation of specific proteins, the clinical and pathological
phenotype of Alzheimer’s disease (AD) exhibits conspicuous vari-
ability within and among patients (1–4). The amyloid cascade hy-
pothesis posits that the seminal event in the pathogenesis of AD is
the misfolding and aggregation of the amyloid-β peptide (Aβ) (5, 6).
In vitro investigations have found that Aβ can aggregate into diverse
amyloid structures that can impose their conformational charac-
teristics onto naive synthetic forms of the protein (7, 8). In Aβ
precursor protein (APP)-transgenic mouse models, polymorphisms
of aggregated Aβ have been demonstrated that subsequently could
be propagated to naive and susceptible host mice (9–11).
Recent work in humans suggests that Aβ can aggregate into
structural variants with distinct pathobiological traits. One such
study used extracted fibrils from AD brains to seed the aggre-
gation of synthetic Aβ in vitro. The resulting synthetic descen-
dants of aggregated Aβ from brain samples provided indirect
evidence for structural heterogeneity of Aβ among AD brains; in
addition, the findings suggested that Aβ assumes a single, dom-
inant conformation within a given brain (12, 13). Another in-
vestigation has shown that the biophysical features of aggregated
Aβ differ significantly in patients with rapidly progressive AD
compared with those with normally progressive disease, indica-
tive of distinct molecular structures of Aβ (14). In an exceptional
example of Aβ aggregate structural variation in AD, a patient
was described as having an extraordinarily high Aβ burden but
a paucity of high-affinity Pittsburgh compound B (PiB) bind-
ing sites (15). More recently, X-ray microdiffraction analysis of
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individual AD brain tissue samples indicated that the amyloid
arrangement of Aβ is polymorphic within and among plaques (16).
Morphologically at the light-microscopic level, it is well
documented that amyloid plaques in AD brains present with
phenotypic variation that typically ranges from diffuse to dense-
cored plaques (17–24). How such morphotypes are linked to the
molecular conformation of the amyloid has not been established.
The characterization of amyloid has been facilitated by a new
class of dyes known as luminescent conjugated oligothiophenes
(LCOs; or luminescent conjugated polythiophenes) (25, 26).
LCO dyes bind to the repetitive cross–β-sheet structures of am-
yloid fibrils and display spectral differences based on the twisting
of the flexible LCO backbone (25, 27). Additionally, it was found
that certain LCOs compete with a Congo red analog (X-34) for
binding to recombinant Aβ-amyloid fibrils as well as AD brain-
derived Aβ, but they do not compete for the PiB binding site
(28). It has been demonstrated that LCOs can detect molecular
differences in Aβ plaque structure in different APP-transgenic
mouse models (10), and in Aβ aggregated in vitro at different
stages of fibrillization (25, 29, 30).
We hypothesized that the phenotypic and histopathological
variability of AD results, at least in part, from variation in the
molecular architecture of aggregated Aβ. To this end, we used
LCOs and biochemical analyses to evaluate the variation and
structural properties of amyloid in the plaques of patients with
AD from different etiological backgrounds [familial forms;
sporadic forms, including the posterior cortical atrophy (PCA)
variant of AD (PCA-AD); and a unique PiB-negative AD case].
Our results provide evidence for the existence of heterogeneous
Aβ-amyloid structures that cluster as clouds across different pa-
tients with AD while encoding conformational characteristics
that can be biologically propagated.
Results
Spectral Characteristics of Plaque Amyloid in AD Brains.We evaluated
plaque amyloid in tissue sections from a cohort of patients with
AD of various etiologies, including familial mutation carriers for
APP (V717I) and PSEN1 (A431E, F105L, and E280A), as well as
cases of typical sporadic AD (sAD) and sporadic PCA-AD (Table
S1). A double-stain combination with two LCOs, quadro-formyl
thiophene acetic acid (qFTAA) and hepta-formyl thiophene ace-
tic acid (hFTAA) (29, 30) (Methods), was used to label amyloid
plaques in fresh-frozen brain sections. Subsequently, the dense
(congophilic) cores of amyloid plaques were spectrally analyzed
for fluorescence emission characteristics (Figs. S1 and S2). Three
brain regions, the midtemporal gyrus (temporal), pericalcarine
gyri (occipital), and midfrontal gyrus (frontal), were investigated
for each patient (Fig. 1A). Preliminary visual inspection under
the fluorescence microscope revealed obvious variation in plaque
appearance even within a tissue section (Fig. 1B).
To determine how the molecular structure of plaque amyloid
varies among brains and brain regions, the mean emission spectra
were calculated for all plaques in each brain region of all subjects.
Pairwise comparisons between individual patients were then per-
formed using a Euclidean distance calculation (Fig. 1 C and D).
This analysis revealed that the spectral signatures of plaque amy-
loid in familial APP V717I and PSEN1 A431E mutation carriers
were most different from the other groups (Fig. 1C). Statistical
analysis of the ratio of the emission peaks for qFTAA (502 nm)
and hFTAA (588 nm) in individual plaque cores confirmed that
the APP V717I and PSEN1 A431E groups were significantly dif-
ferent from most other groups (Fig. 1E). A difference was also
found between sAD and PCA-AD cases (Fig. 1E). Of note, how-
ever, was the striking variability within the sAD group (Fig. 1 C and
E), with one of the samples with a high LCO spectral ratio being a
previously described case with reduced high-affinity binding of PiB
(Fig. 1 C and E).
To further interrogate the variability in LCO spectra among
the groups, all data points from the analysis based on the cor-
relation of fluorescence intensity at 502 nm and 588 nm were
examined (Fig. 1F). Again, the spectral signatures of plaque
amyloid in the different patient groups segregated into notice-
able clouds that partially overlapped each other (Fig. 1F).
Amyloid Plaque Spectral Characteristics Compared with Other
Metrics. To determine whether the results from the LCO spec-
tral analysis of plaques could be explained by factors that affect
amyloid deposition in the brain, LCO ratios were related to
apolipoprotein E (ApoE) genotype, subject age at death, and
postmortem interval (PMI) (Fig. 2). Only sAD and PCA-AD
samples were used to remove obvious confounding effects that
the familial mutations might have on the comparison (e.g.,
younger mean age at death). No correlation was found between
spectral ratio and ApoE status or subject age at death (Fig. 2 A–
C). The correlation found between the spectral ratio and the
PMI disappeared when sAD cases and PCA-AD cases were
analyzed separately, reflecting the overall longer PMI for the
PCA-AD samples (Fig. 2C). Thus, ApoE, age at death, and PMI
are not crucial factors for the observed LCO spectral differences.
To assess whether the LCO results are related to the total Aβ
load or the deposited Aβ species, Aβ was analyzed biochemically
(Fig. S2). Overall, samples from the PSEN1 A431E group had
higher Aβ levels than all other groups. The ratio of Aβ42/40 was
higher in the APP V717I familial mutation carriers compared
with the PSEN1 mutation carriers (Fig. S2). Neither the amount
of Aβ nor the Aβ42/40 ratio differed significantly across the three
neocortical regions; furthermore, the LCO spectra were not
significantly associated with either total Aβ or the Aβ42/40 ratio
when the analysis was confined to sAD and PCA-AD samples
(Fig. 2 D and E).
Proteinase K (PK) resistance has been linked to pathogenic
conformations of Aβ in mouse models and AD brains (11, 31,
32). To determine whether the LCO spectral signatures of the
plaque cores are associated with protease sensitivity, the re-
sistance of aggregated Aβ to proteolysis over time was evaluated
(Fig. S2). No differences among patient groups were observed
(Fig. S2). Furthermore, when only sAD and PCA-AD cases were
considered, there was no significant correlation between the
plaque spectral ratio and Aβ PK resistance (Fig. 2F).
Amyloid Plaque Spectral Characteristics Are Transmissible to Experimental
Mouse Models. We next asked whether the LCO spectral properties
of amyloid plaques can be propagated in vivo by the prion-like
process of molecular conformational templating. To this end,
cortical extracts from AD groups showing the most distinct LCO
spectra, namely, APP V717I, PSEN1 A431E, and sAD, in addition
to the unique PiB-negative sAD case, were injected into the hip-
pocampus of young APP23-transgenic mice (Fig. 3). APP23 mice
were used for this analysis because they have recently been char-
acterized in a seeding activity bioassay in which the precise bi-
ological activity of brain extracts was assessed (33). Before
injection, all extracts were pooled for each AD group and the Aβ
concentration was adjusted to 7.5 pg/μL. Since we found that the
LCO spectral characteristics of plaques did not differ significantly
among the three brain regions, we arbitrarily chose temporal
cortical samples as the source of Aβ seeds.
Inoculated APP23 mice were analyzed 6 mo after injection
(Fig. 3A). In all mice, Aβ deposition was induced in the hippo-
campus (primarily the dentate gyrus) as reported previously (9,
33). While this regional pattern of induction was not discernibly
different among the groups, the amount of induction showed
remarkable differences, with mice injected with APP V717I and
typical sAD extracts manifesting at least twice as much induced
Aβ deposition as mice injected with material from PSEN1 A431E
donors or from the PiB-refractory sAD donor (Fig. 3 A and B).
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Strikingly, when brain sections from the recipient mice were
stained using the same LCO protocol as that used for the hu-
man tissue (Fig. 1), quite remarkable differences in the emission
spectra of individual plaque cores were observed (Fig. 3A). The
mean emission spectra of all seeded hippocampal plaque cores
were computed for each injected mouse, and a Euclidean distance
calculation was applied to determine differences (Fig. 3C). Similar
to the LCO spectral patterns in plaques from the human donors,
seeded amyloid in the PSEN1 A431E-injected mice was most
different from that in the sAD groups, albeit with more variation
(Fig. 3 C and D). For statistical comparison of the experimental
groups, the 502-nm/588-nm spectral ratio was calculated for each
plaque core, and the mean ratios for each injected mouse were
computed (Fig. 3 D and E). The spectral ratios in the different
groups of seeded host mice displayed relatively similar patterns to
those in the donor humans (compare Figs. 1E and 3E); the group
difference was statistically significant between PSEN1 A431E- and
sAD-seeded mice, but the other group differences did not reach
statistical significance. The amount of induced Aβ deposition did
not correlate with the spectral ratio, suggesting these two factors
are independent (Fig. 3F). As with the human tissue, all plaque
cores analyzed in the mice were plotted based on the fluorescence
intensity at 502 nm against 588 nm (Fig. 3G). The plaques in
seeded mice occupied similar clouds within an injection group,
although these clouds showed more overlap in the injected mice
than in the original human tissue (Fig. 1), suggestive of differential
host–agent interactions (9).
Discussion
The extraordinary phenotypic variability of AD (1–3) currently
defies explanation. It is likely that many factors are involved, in-
cluding the age at disease onset, location of the initial abnor-
malities in the brain and their pattern of spread, the inflammatory
response to the lesions, and the presence of comorbid conditions.
The present findings support growing evidence that the hetero-
geneity of AD may also be influenced by the heterogeneous mo-
lecular architecture of misfolded Aβ in the brain.
Using synthetic Aβ that was aggregated in vitro, multimeric Aβ
assemblies have been shown to assume diverse tertiary and
quaternary structures (13, 34–37). These findings have greatly
augmented our understanding of Aβ fibril structure, but their
relevance to the pathobiology of Aβ in vivo, in the native disease
Fig. 1. Subtypes of AD display distinguishable clouds
of amyloid conformational variants. (A) Combination
of two LCOs, qFTAA and hFTAA, was used to stain Aβ
plaques in three different neocortical regions (tem-
poral: midtemporal gyrus, T; occipital: pericalcarine
gyri, O; frontal: midfrontal gyrus, F) of postmortem
brain tissue from familial AD (APP V717I, PSEN1
A431E, PSEN1 F105L, and PSEN1 E280A), typical sAD,
and sporadic PCA-AD cases. (B) Shown is an LCO-
stained section of the temporal cortex from a patient
with sAD (AD16; also patient information in Table S1).
Note that a variety of different fluorescence emission
patterns are present in a single brain sample. (Scale
bars: Left, 200 μm; Right, 20 μm.) (C and D) Plaques
were randomly selected, and for each plaque core,
the fluorescence intensity was measured at 22 wave-
lengths to produce a continuous fluorescence spec-
trum (40–60 plaques were analyzed per region for
each brain sample; also Fig. S1). Each line in D rep-
resents the mean spectrum for a particular brain area
in all patients in a given subgroup. A heat map
depicting the difference of Euclidean distances be-
tween the mean spectra (of all 22 fluorescence mea-
surements) for brain regions of individual patients is
shown in C. Larger and more darkly colored circles
represent more dissimilar spectra. The labels repre-
sent patient numbers with the temporal, occipital,
and frontal regions repeating as sets of three (from
top to bottom). Note the variability within the sAD
group, with some regions yielding emission spectra
more similar to those of the familial groups (for AD2,
only temporal and occipital cortex tissue was avail-
able for analysis). (E) For statistical analysis, the fluo-
rescence intensity at 502 nm and 588 nm (which
represent the fluorescence emission peaks of qFTAA
and hFTAA, respectively; Fig. S1C) was analyzed for
each region of each patient. Two-way ANOVA (brain
region × AD subtype) revealed a significant effect for
subtype [F(5,101) = 33.07, P < 0.0001], but not for brain
region [F(2,101) = 0.0681, P = 0.9343] or interaction
between region and subtype [F(10,101) = 0.7829, P =
0.6451]. Tukey’s multiple comparisons revealed sig-
nificant differences between APP V717I vs. PSEN1
E280A, sAD and PCA-AD; PSEN1 A431E vs. PSEN1
F105L, PSEN1 E280A, sAD and PCA-AD; PSEN1 F105L
vs. PSEN1 E280A, sAD and PCA-AD; and sAD vs. PCA-
AD (all probabilities at least P < 0.05). An exceptional sAD case, AD34 (denoted by arrows in C and E), is a previously described case with reduced high-affinity
binding of the PiB radioligand (15). Error bars represent the SEM. (F) Scatter plot of all plaques analyzed using fluorescence at 588 nm vs. 502 nm per AD subgroup
reveals that plaque spectral properties within the AD subgroups occupy distinct clouds, which overlap between AD subgroups.








state, remains uncertain (38). For instance, in most cases, these
experiments involved the analysis of a single isoform of Aβ, ei-
ther 40 aa or 42 aa long, whereas there are multiple isoforms,
fragments, and posttranslational modifications of Aβ in the living
brain (39, 40).
Tycko and coworkers (12, 13) have demonstrated that Aβ
derived from different cases of AD is able to induce synthetic Aβ
to assemble into corresponding structural “strains,” and the au-
thors suggest that a single Aβ structure predominates in a par-
ticular AD brain. Our observations generally support the concept
of a predominant, case-specific Aβ strain in that the mean
LCO spectral emission of plaque cores (where the Aβ adopts an
amyloid conformation) was similar in different cortical regions
of each patient, regardless of the AD subtype. However, direct
microscopic analysis of individual plaque cores with LCOs
allowed us to determine that minor populations of Aβ aggregates
with different molecular architectures also are present within a
given AD brain. We therefore speculate that the presence of
these structural variants in other investigations (12, 13) may have
been masked by the conformational selection and in vitro pro-
pagation of a dominant strain in preparation for the NMR ana-
lysis. In support of this possibility, and in agreement with our
findings, X-ray microdiffraction analysis has revealed structural
polymorphism among amyloid plaques within the same tissue
section (16).
In light of the intra- and interindividual variability in the LCO
spectral characteristics of plaque amyloid, it is remarkable that
we still found differences among patient subgroups, particularly
between some of the familial AD and sAD cases (note that the
familial AD mutations in the present study do not change the Aβ
sequence). Neuropathological analyses also have revealed dif-
ferences in plaque morphotypes between some familial AD
mutations and sAD (18, 20, 23). However, while these observa-
tions were made on Aβ-immunostained plaques, our LCO-based
spectral analysis was confined to the core of the plaque, and thus
to Aβ in the amyloid conformation.
We were somewhat surprised to observe differences in the
amyloid spectral characteristics between typical patients with
sAD and patients with the PCA variant of AD. Both the regional
distribution of amyloid and the clinical phenotype are different
in PCA-AD and sAD (41). A previous NMR analysis did not
indicate molecular structural differences between PCA-AD and
sAD (13), but, as noted above, the analysis could have been
confounded by conformational selection of Aβ species best
suited for the seeded in vitro growth of fibrils. The clinicopath-
ological distinctiveness of PCA-AD appears to result, in part,
from a disease-specific site of origin and/or pattern of Aβ dis-
semination (41), but our findings indicate that the molecular
architecture of misfolded Aβ may also play a role. Similarly, in a
rapidly progressive subtype of AD, there is biochemical evidence
for increased conformational heterogeneity of Aβ42 (14), and a
recent NMR study using seeded growth of synthetic Aβ fibrils
from brain-derived material supports this finding (13).
In the present study, the LCO spectral characteristics of amy-
loid in plaques did not correspond in a consistent way to the PK
resistance or the abundance of the two major Aβ species (Aβ40
and Aβ42) in tissue homogenates. One possible explanation for
this is that the spectral analysis and biochemical tests do not probe
identical populations of Aβ [i.e., the amyloid core (LCOs) vs. the
total pool of aggregated Aβ (biochemistry)]. Another possibility is
that variation in amyloid structure revealed by the LCO spectral
analysis is more sensitive at identifying subtle differences that
biochemical analyses currently are unable to detect. Elucidation of
the mechanisms underlying the architectural variability of Aβ in
plaques could reveal pathogenically important targets for the de-
velopment of personalized treatments for AD.
LCO binding and spectra are dependent on the orientation,
side-chain interactions, and packing of amyloid fibrils, and the
ability of LCOs to recognize amyloid features in protein pathol-
ogies has been well characterized (25). These ligands thus are
exquisitely sensitive indicators of molecular architectural differ-
ences in proteopathic fibrils, for example, the strain-like diversity
of prion protein aggregates (42). In recent studies, it has been
shown that the arrangement and packing of Aβ-amyloid fibrils
influence the spectral output of the LCOs, especially when the
ligands are used in combination (29, 30, 43). Since LCO spectra
indicate the presence of different structural conformations of Aβ,
we predicted from previous experiments that these properties
should be transmissible to susceptible hosts (44). Our studies in
APP-transgenic mice confirm that Aβ-rich brain extracts from
different subtypes of AD seed Aβ deposits that are correspond-
ingly differentiable using LCOs. The LCO spectral traits of amy-
loid in the seeded transgenic mice did not perfectly mirror those of
the human donor tissue; however, this is expected because both
Fig. 2. Spectral properties of LCO-labeled amyloid plaques are not
explained by ApoE genotype, patient age, PMI, or Aβ biochemistry. (A) LCO
spectral ratio of fluorescence at 502 nm and 588 nm separated into ApoE
genotype subgroups (mean of the three regions; Fig. 1E; only subjects with
sAD and PCA-AD were used to remove the confounding effects of the fa-
milial mutations on the data; orange triangles, sAD; cyan diamonds, PCA-
AD). The Mann–Whitney test was used to determine significance between
ApoE 3/3 vs. 3/4 cases (P = 0.4221). Error bars represent the SEM. (B) LCO
spectral ratio vs. patient age. Nonparametric Spearman correlation: P = 0.38.
(C) LCO spectral ratio vs. PMI. Nonparametric Spearman correlation: P =
0.29 for PCA-AD and P = 0.32 for sAD. (D and E) LCO spectral ratios vs. ELISA
measurements (mean of all brain regions) of Aβ 40 + 42 and the Aβ42/
40 ratio (Aβ measurements are shown in Fig. S2). Nonparametric Spearman
correlation analysis yielded P = 0.26 and P = 0.81, respectively. (F) LCO
spectral ratio vs. Aβ remaining after 1 h of digestion with PK (mean of all
brain regions). Nonparametric Spearman correlation: P = 0.78. Detailed re-
sults for PK digestion are shown in Fig. S3.
4 of 6 | www.pnas.org/cgi/doi/10.1073/pnas.1713215114 Rasmussen et al.
the agent and host influence the propagation of Aβ and the
characteristics of the resulting deposits (9). In addition, the mice
were seeded with extracts of brain tissue, which may have a seed
composition that differs from that in the plaque cores. The exis-
tence of LCO spectral clouds that only partially recapitulate those
of the AD donors thus may reflect the composition of seeds in the
donor extract as well as the Darwinian selection of different Aβ
strains in the host mice (45).
The spectral properties of LCOs bound to plaques change as
APP-transgenic mice grow older, suggestive of age-related con-
formational rearrangement of the Aβ (30). Thus, it is possible
that the spectral variation of plaques in individual patients with
AD at least partially reflects the presence of plaques of different
ages. The AD brains analyzed in the present study were all from
patients with end-stage disease, at which point amyloid, per se,
may no longer be the primary driver of the disease (46). Nev-
ertheless, the deposited amyloid shows remarkable LCO spectral
variability among patients with sporadic end-stage AD. Fur-
thermore, the LCO spectral signals detected within an individual
brain, although generally similar in the three cortical regions,
constitute a cloud of variable emission spectra. It is possible that
the composition of the amyloid may be more complex late in the
pathogenic process than at earlier time points. If so, the LCO
spectra might reveal more clearly differentiable disease patterns
in the earlier stages. Analysis of incipient amyloid plaques in
persons who died of other causes before the onset of AD
symptoms will be informative in this regard. Finally, it will be
important to establish the relationship between the variant mo-
lecular structure of plaque cores and the pathobiologically po-
tent oligomeric forms of Aβ (31, 47).
The present findings have several implications for diagnostics
and treatment. Variations in amyloid structure are likely a com-
plicating factor when determining the distribution and severity of
Aβ deposition by PET imaging in patients with AD, as demon-
strated by an unusual case of AD with very high Aβ levels in the
brain but negligible high-affinity binding of PiB (15). We found
that the plaque cores in this case displayed an LCO spectral pattern
that differed from that of most other sAD cases. If antibody
binding to Aβ is similarly influenced by the molecular architecture
of the misfolded protein, it is conceivable that a particular mono-
clonal antibody might fail to recognize the full range of Aβ ag-
gregates that can arise within a brain and among different patients.
Thus, it may be advantageous to use multiple antibodies to create a
“polyclonal” mixture for treatment of Aβ pathology. Finally, future
work should investigate the therapeutic potential of LCOs for AD
and other proteopathies, as has been shown for prion disease (27),
and, additionally, determine the feasibility of using LCOs to ex-
amine Aβ aggregates in bodily fluids such as cerebrospinal fluid
and blood to augment the personalized diagnosis of AD.
Methods
Patient Samples. Fresh tissue samples were obtained from the midtemporal
gyrus (temporal), pericalcarine gyri (occipital), and midfrontal gyrus (frontal)
of 40 clinically and pathologically diagnosed AD cases (Table S1). The tissues
were acquired under the proper Institutional Review Board protocols from
the Tübingen Review Board for the work in the Queen Square Brain Bank at
University College London samples (202/2016BO2), the Emory University
Alzheimer’s Disease Research Center to do the work on these samples (IRB
00045782), and the University of Antioquia, Medellin, Colombia (09-10-232).
Informed consent was given by families (see SI Methods for details).
Fig. 3. Variant conformations of aggregated Aβ
can be induced by exogenous seeding in APP-
transgenic mice. (A) Seeding extracts were prepared
from the middle temporal gyrus of pooled (n = 3)
brain samples from human APP V717I, PSEN1 A431E,
sAD [AD15, AD16, and AD24; patients collected in
the same year at the same site (Emory University)]
and a single PiB-refractory sAD case (AD34) (Fig. 1
and Table S1). Aβ concentrations of the seeding
extracts were adjusted to 7.5 pg/μL (Methods). Ex-
tracts were injected into young (4-mo-old) female
APP23 mice [APP V717I (n = 6), PSEN1 A431E (n = 7),
sAD (n = 8), and PiB-negative (neg.) sAD (n = 6)].
Brains of recipient mice were analyzed 6 mo after
injection. Induced Aβ deposition in the hippocampus
was stained with a polyclonal Aβ antibody (Top) or
the LCO double-staining protocol (Bottom). (Scale
bars: Top, 200 μm; Bottom, 50 μm.) (B) Stereological
quantification of Aβ-immunostained area in the
hippocampus. The Kruskal–Wallis test followed by
Dunn’s multiple comparison test revealed significant
differences in the degree of induction between APP
V717I vs. PSEN1 A431E (P < 0.05) donors, PiB-neg.
sAD vs. APP V717I donors (P < 0.001), and PiB-neg.
sAD vs. sAD donors (P < 0.01). Error bars represent
SEM. (C) Heat map of the Euclidean distance be-
tween LCO spectra calculated for each mouse (de-
tails are provided in Fig. 1). Larger and more darkly
colored circles represent more dissimilar spectra. (D)
Mean LCO fluorescence spectra of induced plaque
cores for mice injected with different human ex-
tracts (20–30 plaques were analyzed per mouse;
details are provided in Fig. 1). (E) For statistical
analysis, the mean ratio of the fluorescence intensity
at 502 nm and 588 nm was calculated for each
mouse. The Kruskal–Wallis test followed by Dunn’s
multiple comparison test revealed significantly different spectral signatures in plaques seeded by PSEN1 A431E vs. sAD brain extracts (P < 0.05). Error bars
represent the SEM. (F) Amount of Aβ induction did not correlate with the LCO spectral ratio of the induced amyloid (nonparametric Spearman correlation, P =
0.9687). (G) Scatter plot of LCO fluorescence spectra emitted by all plaques analyzed in seeded mice demonstrates an overall preservation of clustering among
the groups, although the group differences were less distinct compared with plaque spectra in the original human donor samples (Fig. 1).








LCO Staining Spectral Analysis. Two LCO variants, qFTAA and hFTAA,were used
to stain fresh-frozen tissue (30). Amyloid plaques were randomly chosen, and
continuous emission spectra were acquired (Figs. S1 and S2). Only the dense
cores of plaques were analyzed. Details are provided in SI Methods.
Aβ Quantification, Mass Spectrometry, and PK Digestion. For Aβ quantification,
human tissue was extracted with 70% formic acid. Extracts were also analyzed
by targeted mass spectrometry for Aβ (48). PK digestion was carried out on
fresh tissue at 37 °C for 0, 1, 2, and 4 h and analyzed with Aβ immunoblots.
Details are provided in SI Methods.
In Vivo Inoculations of the Mice. Seeding extracts were generated from the
middle temporal gyrus (33). Pooled extracts [APP V717I (AD1–3), PSEN1 A431E
(AD4–6), and typical sAD (AD15, AD16, and AD24)] and the distinct PiB-negative
sAD case (AD34) (Table S1) were adjusted to the same Aβ concentration. In-
trahippocampal injections were done in 4-mo-old APP23 mice (49). After 6 mo
of incubation, brain sections were Aβ-immunostained and quantified (50, 51).
Sections were also stained with the LCOs. All mouse experiments were ap-
proved by the local animal care and use committee in Baden-Württemburg,
Germany (Regierungspräsidium Tübingen). Details are provided in SI Methods.
Statistical Analysis. GraphPad Prism (v.5) was used for statistical analyses.
R (v. 3.3.2) was used for Euclidean distances. Details are provided in SIMethods.
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SI Methods
Patient Samples. Tissue samples were obtained from the mid-
temporal gyrus (temporal), pericalcarine gyri (occipital), and mid-
frontal gyrus (frontal) of 40 clinically and pathologically diagnosed
AD cases (Table S1). Among them, 13 familial cases (AD 1–13) had
the following mutations: V717I in APP, three cases; A431E in
PSEN1, three cases; F105L in PSEN1, two cases; and E280A in
PSEN1, five cases. The remaining 27 cases had a typical sporadic
(idiopathic) etiology (AD14–34) or a sporadic PCA variant of AD
(AD35–40). The samples were obtained from four different sources,
the Emory University Alzheimer’s Disease Research Center; the
Dementia Laboratory, Department of Pathology and Laboratory
Medicine, Indiana University School of Medicine; the Queen
Square Brain Bank at University College London; and the Institute
of Medical Research, Faculty of Medicine, University of Antioquia,
Medellín, Colombia. Human postmortem tissues were acquired
under proper Institutional Review Board protocols with consent
from families.
LCO Staining and Immunohistochemistry on Patient Samples. Two
different LCO variants, qFTAA and hFTAA, were used for de-
tection and analysis of amyloid pathology. Fresh-frozen human
tissue was cut into 12-μm-thick sections on a cryotome, dried at
room temperature (RT) overnight, and stored at −80 °C. Tissue
was thawed, air-dried, and then double-stained with qFTAA and
hFTAA (2.4 μM qFTAA and 0.77 μM hFTAA in PBS) similar to
a previously described protocol (30). Sections were incubated for
30 min at RT in the dark.
Immunohistochemistry was performed using a polyclonal pri-
mary antibody directed against Aβ (CN6) as previously described
(50). Staining with Congo red and Thioflavin-S for amyloid was
conducted according to standard protocols.
Spectral Analysis. Spectra were acquired on a Zeiss LSM 510
META confocal microscope equipped with an argon 458-nm laser
for excitation and a spectral detector (Carl Zeiss MicroImaging
GmbH). A 40× oil-immersion objective (1.3 N.A.; Zeiss) was used
for spectral imaging of Aβ-amyloid cores. Continuous emission
spectra were acquired from 470 to 695 nm. The amyloid plaques
were randomly chosen, and three regions of interest were mea-
sured in the core of each deposit (Figs. S1 and S2). Only the dense
cores of plaques were analyzed. Other types of Aβ deposits (dif-
fuse plaques, intracellular Aβ, and cerebral amyloid angiopathy)
were excluded. Care was taken to avoid interference of lipofuscin-
induced autofluorescence with LCO signals; the use of spectral
imaging allowed us to distinguish between the distinct LCO fluo-
rescence spectrum and unwanted autofluorescence.
A total of 15 to 25 Aβ plaque cores were measured in each
region, totaling 45–60 plaques per patient. After the spectral
measurements, all emission spectra were normalized to their
respective maxima. The mean spectral signature of each plaque
core was calculated before averaging the values for each brain
area in each patient. The ratio of the intensity of emitted light at
the blue-shifted peak (502 nm) and red-shifted peak (588 nm)
was used as a parameter for spectral distinction of different Aβ
deposits. The peaks of the spectra were selected to maximize the
spectral distinction.
For the heat map of Euclidean distance calculation, the average
spectrum from 470 nm to 695 nm was calculated for each brain
region. Different spectra were then compared in two samples




ðADx470nm −ADy470nmÞ2 + . . . + ðADx695nm −ADy695nmÞ2
vuut .
In short, the “square-root of the sum-of-squared-differences”
was calculated between two samples using the 22 wavelength
measurements of fluorescence intensity. This pairwise calcula-
tion was completed for every sample pair used in the study. The
output of these calculations is then displayed as a heat map,
with larger and more darkly colored circles representing a large
Euclidean distance (more different emission spectra). This heat
map represents the comparison between samples for the entire
emission curve. Further statistical comparisons between sam-
ples were undertaken using the ratio of the fluorescence inten-
sity at two wavelengths (502 nm/588 nm) representing the peaks
of fluorescence for the two dyes used in this study. The Euclid-
ean distance calculation and the heat map were generated in
R (v. 3.3.2).
ECL-Based Multiarray for Aβ Quantification. Human tissue was ho-
mogenized in PBS (10% wt/vol) using the Precellys system with a
2 × 20-s cycle at 5,500 rpm (Precellys24 Homogenizer, EQ03119-
200-RD000.0, Bertin Instruments). Samples were then extracted
with 70% formic acid (final concentration) and centrifuged at
25,000 × g for 60 min at 4 °C. Supernatants were collected and
neutralized with buffer (1 M Tris base, 0.5 M Na2NPO4, 0.05%
NaN3) before analysis with a V-PLEX Peptide Panel 1 (6E10) Aβ
kit from Meso Scale Discovery following the manufacturer’s
specifications.
PK Digestion. Samples homogenized with the Precellys system de-
scribed previously were centrifuged at 800 × g for 5 min at 4 °C, and
the supernatant was collected. Protein concentrations were de-
termined using a bicinchoninic acid total protein kit, and samples
were then digested with 1 μg of PK/3 μg of protein at 37 °C.
Samples were collected for analysis at 0, 1, 2, and 4 h and stopped
with 2 mM PMSF. Samples were heated to 70 °C for 10 min in
LDS sample buffer (Invitrogen), loaded onto 4–12% Bis-Tris
precast gels, and run at 125 V for 44 min. Gels were transferred
onto nitrocellulose and subsequently boiled at 95 °C for 5 min in
PBS. Blocking was achieved with 4% skim milk in PBS with 0.05%
Tween-20 for 60 min at RT. Membranes were probed with anti-
body 6E10 (1:5,000) overnight at 4 °C and then incubated with a
goat anti-mouse secondary antibody (1:30,000) for 60 min. De-
velopment was carried out with Dura Extended Duration Substrate
(Pierce) before exposure on Hyperfilm ECL film (Amersham).
Band intensities were quantified using ImageJ software (NIH).
Mass Spectrometry.Human tissue was homogenized in PBS (10%
wt/vol) using the Precellys system with a 2 × 20-s cycle at
5,500 rpm (Precellys24 Homogenizer, EQ03119-200-RD000.0,
Bertin Instruments). Samples were then extracted with 70%
formic acid, centrifuged at 25,000 × g for 60 min at 4 °C, and
dried in a speedvac. The samples were reconstituted in 200 μL of
formic acid for 30 min and then neutralized to pH 7 using 0.5 M
Tris. Aβs were then immunoprecipitated using Aβ-specific anti-
bodies [antibodies 6E10 and 4G8 (Signet Laboratories)] coupled
to magnetic Dynabeads M-280 Sheep Anti-Mouse IgG (Invi-
trogen) as described previously (48). Mass spectrometry was
performed using a MALDI TOF/TOF instrument (UltraFleXtreme;
Bruker Daltonics). Analysis was completed as described
previously (48).
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In Vivo Inoculations.Given that the LCO spectral characteristics of
plaque cores did not differ among the three brain regions, we
prepared the donor inoculum from temporal cortical samples only.
Seeding extracts were generated from a 10% (wt/vol) homogenate
of the middle temporal gyrus using the Precellys system as de-
scribed above. The homogenates were subsequently centrifuged at
3,000 × g for 5 min at 4 °C. The supernatants were then collected
and stored at −80 °C. Quantification of Aβ in the extracts was
performed after formic acid extraction using the MesoScale
platform. Seeding extracts were pooled for the APP V717I (AD1–
3), PSEN1 A431E (AD4–6), and typical sAD (AD15, AD16, and
AD24) groups (Table S1), while the PiB-refractory case remained
distinct. All samples then were adjusted to the same total Aβ
concentration (7.5 pg/mL) using PBS as a diluent.
Predepositing 4-mo-old female APP23 mice (49) were injected
bilaterally (2.5 μL each) with seeding extracts from the APP
V717I (n = 6), PSEN1 A431E (n = 7), typical sAD (n = 8), and
PiB-negative sAD (n = 6) cases following anesthesia with ket-
amine/xylazine (100 mg/kg to 10 mg/kg of body weight). Injec-
tions were targeted to the hippocampus (anteroposterior, −2.5 mm;
left/right, ±2.0 mm; dorsoventral, −1.8 mm) and delivered with a
Hamilton syringe at a speed of 1.25 μL/min. The syringe was kept in
place for an additional 2 min and then slowly withdrawn. The
surgical incision then was closed, and the mice were closely mon-
itored until regaining consciousness. All experimental procedures
with the mice were carried out in accordance with the veterinary
office regulations of Baden-Württemberg (Germany) and ap-
proved by the local animal care and use committees (Regierung-
spräsidium Tübingen).
Histological Analysis of theMice.After 6 mo of incubation following
infusion of brain extracts, the mice were killed by deep anesthesia
(250 mg/kg ketamine and 25 mg/kg xylazine) and transcardial
perfusion with ice-cold PBS. The brains were immersion-fixed in
4% paraformaldehyde-PBS for 48 h and then cryoprotected in
30% sucrose-PBS. After snap-freezing in methyl butane, brains
were sectioned at 25-μm thickness on a freezing-sliding micro-
tome (Microm; Thermo Scientific) and collected in 12-well
plates (every 12th section was represented in a well) containing
cryoprotectant solution (35% ethylene glycerol and 25% glycerol
in PBS). Sections were immunostained for Aβ using either a
polyclonal antibody (discussed above) and Vectastain Elite ABC
kit (Vector Laboratories) (50) or the double-stain LCO protocol
outlined for the human tissue (discussed above).
The hippocampus (every 12th section) of each animal was
analyzed for the area occupied by Aβ-positive immunostaining
with stereological analysis on a video-microscopy system (Zeiss
Axioskop 2) equipped with a motorized x-y-z stage and Stereo
Investigator software (MicroBrightField) as previously described
(51). The area occupied by Aβ-positive staining was determined
using 2D sectors in a single focal plane (magnification of 20×/
0.45-N.A. objective) as sampling sites.
Statistical Analysis. To test normality, the D’Agostino–Pearson
omnibus normality test was used. For two-way ANOVA followed
by Tukey’s multiple comparisons test, data were logarithmically
transformed when not normally distributed. The nonparamet-
ric Spearman correlation or Kruskal–Wallis test followed by
Dunn’s multiple comparison test were used in all other analyses.
GraphPad Prism (v.5) was used for all statistical analyses.
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Fig. S1. Analysis of LCO-stained amyloid plaque cores. (A and B) Two representative images of the temporal cortical region of a sAD case (AD16) that was
stained with hFTAA and qFTAA. For each plaque core, three regions of interest (circle/cross symbols) were set and the fluorescence intensity was measured at
22 wavelengths. A plaque core with an emission peak in the blue spectrum is shown in A, whereas B shows a plaque core with an emission peak in the red
spectrum. For each plaque core, the mean was calculated from the three regions of interest. Diffuse plaques, cerebral amyloid angiopathy, and intracellular
aggregates were not included in this analysis. (Scale bars: 20 μm.) (C) For comparative illustration, the spectra of the single-LCO dyes hFTAA and qFTAA are
shown. Single staining with either hFTAA or qFTAA was performed on three different patients (AD17, AD20, and AD23), and the individual spectra were
calculated from 60 different plaques. qFTAA shows a peak around 500 nm, whereas hFTAA shows two peaks around 550 and 590 nm.
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Fig. S2. Double staining of LCOs combined with other amyloid markers. Tissue from a sAD case (AD17) was stained with hFTAA and qFTAA and in adjacent
sections with Congo Red (CR), Thioflavin-S (ThS), or the polyclonal Aβ antibody CN6. (A) Three blue-shifted plaques are shown with adjacent sections stained for
CR (Inset shows birefringence), ThS, or CN6. (B) Three red-shifted plaques are shown with adjacent sections stained for CR (Inset shows birefringence), ThS, or
CN6. No differences in staining between the blue- and red-shifted plaque (cores) were detected with CR, ThS, or the Aβ antibody. (Scale bars: 20 μm.)
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Fig. S3. Biochemical analysis of brain tissue from different AD subtypes. Levels of total Aβ40 + Aβ42 (A) and Aβ 42/40 ratio (B) for each patient (formic acid
extraction before 25,000 × g centrifugation) were assessed by ECL-based multiarray. Two-way ANOVA (brain region × subtype) revealed significantly different
levels of Aβ among AD subtypes [F(4,89) = 8.278, P < 0.0001], but no significant differences among brain regions [F(2,89) = 2.375, P = 0.0989]. No subtype × region
interaction was found [F(8,89) = 0.8558, P = 0.5568]. Tukey’s multiple comparisons test revealed significant differences in total Aβ between APP V717I vs. PSEN1
A431E and sAD; PSEN1 A431E vs. PSEN1 F105L, sAD, and PCA-AD (all probabilities at least P < 0.05). Two-way ANOVA also revealed significantly different Aβ42/
40 ratios in the AD subtypes [F(4,89) = 4.744, P = 0.0016], but no significant differences among brain regions [F(2,89) = 0.3785, P = 0.6860] or in the subtype ×
region interaction [F(8,89) = 0.2835, P = 0.9698]. Tukey’s multiple comparisons test revealed significant differences in the Aβ42/40 ratio between APP V717I vs.
PSEN1 A431E and PSEN1 F105L; PSEN1 A431E vs. sAD (all probabilities at least P < 0.05). (C–E) PK digestion of brain samples was used to determine protease
resistance of Aβ over time (0, 1, 2, and 4 h), expressed as the fraction remaining after digestion compared with the undigested sample. Brain regions were
analyzed individually. No significant differences were found among patient subtypes using two-way ANOVA (time × subtype) for the temporal [F(4,30) = 1.197,
P = 0.3325], occipital [F(4,30) = 2.080, P = 0.1083], or frontal [F(4,29) = 2.184, P = 0.0957] region. Significant differences for the time effect were seen in the
temporal [F(3,90) = 106.7, P < 0.0001], occipital [F(3,90) = 152.9, P < 0.0001], and frontal [F(3,87) = 134.5, P < 0.0001] regions. Interactions were not significant in the
temporal [F(12,90) = 1.351, P = 0.2049], occipital [F(12,90) = 1.211, P = 0.2877], or frontal [F(12,87) = 1.717, P = 0.0767] region. Note that PSEN1 E280A cases were not
included for biochemical analysis because fresh-frozen tissue samples were not available when other measurements were completed. (F) Mass spectrometry
analysis of the brain samples used for injections (Fig. 3) revealed that all samples contained Aβ1–42, Aβ4–42, and pGlu3–42, with APP V717I samples containing
additional Aβx–42 peptide species and patients with PSEN1 A431E and sAD harboring Aβ1–40. The PiB refractory case also had abundant Aβ1–40 as well as Aβ1–
38 in the tissue.
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Table S1. Patient information
Case Etiology Age, y Sex PMI, h ApoE status
AD1 APP V717I 45 M 4.0 n.a.
AD2 APP V717I 49 F 2.7 E3/3
AD3 APP V717I 54 F 5.3 E3/3
AD4 PSEN1 A431E 43 F 4.0 E3/3
AD5 PSEN1 A431E 47 n.a. n.a. E3/3
AD6 PSEN1 A431E 44 M n.a. E3/3
AD7 PSEN1 F105L 68 F 36.0 E2/3
AD8 PSEN1 F105L 67 F 8.0 E2/3
AD9 PSEN1 E280A 52 M 4.8 E3/3
AD10 PSEN1 E280A 42 F 6.5 E3/3
AD11 PSEN1 E280A 63 F 6.5 E3/3
AD12 PSEN1 E280A 63 M 3.8 E3/3
AD13 PSEN1 E280A 58 M 3.5 E3/3
AD14 sAD 80 F 25.8 n.a.
AD15 sAD 62 M 8.5 E2/3
AD16 sAD 81 F 17.7 E3/3
AD17 sAD 70 M 8.5 E3/3
AD18 sAD 81 F n.a. E3/3
AD19 sAD 62 F 6.0 E3/3
AD20 sAD 74 M 2.5 E3/3
AD21 sAD 54 M 5.5 E3/3
AD22 sAD 91 F 3.0 E3/3
AD23 sAD 81 M 4.0 E3/3
AD24 sAD 89 M 49.0 E3/4
AD25 sAD 64 M 9.0 E3/4
AD26 sAD 87 F 6.0 E3/4
AD27 sAD 58 F 6.0 E3/4
AD28 sAD 77 M 6.0 E3/4
AD29 sAD 88 M 9.0 E3/4
AD30 sAD 70 F 46.9 E3/3
AD31 sAD 67 M 28.6 n.a.
AD32 sAD 77 M 90.1 E4/4
AD33 sAD 76 F 26.8 n.a.
AD34* sAD 72 F 3.0 E3/4
AD35 PCA-AD 76 M 50.3 E3/3
AD36 PCA-AD 71 M 57.5 E3/4
AD37 PCA-AD 68 F 86.8 E3/4
AD38 PCA-AD 88 F 40.3 E3/3
AD39 PCA-AD 71 M 47.6 E3/3
AD40 PCA-AD 65 F 46.6 n.a.
F, female; M, male; n.a., information not available.
*PiB-negative sAD case: AD34.
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